NASDAQ:ATOSAtossa Genetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Atossa Genetics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.48 -0.10 (-6.33 %) (As of 04/10/2020 08:21 AM ET) Add Compare Share Today's Range$1.45Now: $1.48▼$1.6550-Day Range$0.79MA: $1.13▼$1.5852-Week Range$0.76Now: $1.48▼$4.26Volume258,303 shsAverage Volume531,949 shsMarket Capitalization$13.51 millionP/E RatioN/ADividend YieldN/ABeta2.1 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Atossa Genetics. Previous Next 2.4 Community Rank Outperform VotesAtossa Genetics has received 197 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAtossa Genetics has received 215 “underperform” votes. (Add your “underperform” vote.)Community SentimentAtossa Genetics has received 52.18% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote “Outperform” if you believe ATOS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAtossa Genetics does not currently pay a dividend.Dividend GrowthAtossa Genetics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atossa Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Atossa Genetics is held by insiders.Percentage Held by InstitutionsOnly 3.78% of the stock of Atossa Genetics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Atossa Genetics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atossa Genetics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtossa Genetics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATOS Previous Symbol CUSIPN/A CIK1488039 Webhttp://www.atossagenetics.com/ Phone206-325-6086Debt Debt-to-Equity RatioN/A Current Ratio10.82 Quick Ratio10.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book1.08Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-17,240,000.00 Net MarginsN/A Return on Equity-110.33% Return on Assets-97.51%Miscellaneous Employees4 Outstanding Shares9,130,000Market Cap$13.51 million Next Earnings Date5/11/2020 (Estimated) OptionableNot Optionable Receive ATOS News and Ratings via Email Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ATOS Rates by TradingView Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions How has Atossa Genetics' stock been impacted by COVID-19 (Coronavirus)? Atossa Genetics' stock was trading at $0.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATOS stock has increased by 68.2% and is now trading at $1.48. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Atossa Genetics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atossa Genetics. When is Atossa Genetics' next earnings date? Atossa Genetics is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Atossa Genetics. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc (NASDAQ:ATOS) announced its quarterly earnings data on Thursday, March, 26th. The company reported ($0.26) EPS for the quarter, beating the Zacks' consensus estimate of ($0.33) by $0.07. View Atossa Genetics' earnings history. When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work? Atossa Genetics shares reverse split on the morning of Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split. Has Atossa Genetics been receiving favorable news coverage? Media coverage about ATOS stock has trended very negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Atossa Genetics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAtossa Genetics. Who are some of Atossa Genetics' key competitors? Some companies that are related to Atossa Genetics include Pro-Dex (PDEX), SANUWAVE Health (SNWV), Nephros (NEPH), Nephros (NEPHD), Apollo Endosurgery (APEN), Delcath Systems (DCTH), Sensus Healthcare (SRTS), Arch Therapeutics (ARTH), Neuronetics (STIM), Biostage (BSTG), STRATA Skin Sciences (SSKN), Invo Bioscience (IVOB), Motus GI (MOTS), T2 Biosystems (TTOO) and Interpace Diagnostics Group (IDXG). What other stocks do shareholders of Atossa Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Genetics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Amarin (AMRN), Biopharmx (BPMX), Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), NVIDIA (NVDA), vTv Therapeutics (VTVT), Vaxart (VXRT) and Anavex Life Sciences (AVXL). Who are Atossa Genetics' key executives? Atossa Genetics' management team includes the following people: Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical AffairsDr. Jack Cuzick, Member of Scientific Advisory Board What is Atossa Genetics' stock symbol? Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS." How do I buy shares of Atossa Genetics? Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Atossa Genetics' stock price today? One share of ATOS stock can currently be purchased for approximately $1.48. How big of a company is Atossa Genetics? Atossa Genetics has a market capitalization of $13.51 million. Atossa Genetics employs 4 workers across the globe. View additional information about Atossa Genetics. What is Atossa Genetics' official website? The official website for Atossa Genetics is http://www.atossagenetics.com/. How can I contact Atossa Genetics? Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Reverse Stock Split
